These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33073195)

  • 1. Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21.
    Pan J; Parlee SD; Brunel FM; Li P; Lu W; Perez-Tilve D; Liu F; Finan B; Kharitonenkov A; DiMarchi RD
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):978-986. PubMed ID: 33073195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.
    Agrawal A; Parlee S; Perez-Tilve D; Li P; Pan J; Mroz PA; Kruse Hansen AM; Andersen B; Finan B; Kharitonenkov A; DiMarchi RD
    Mol Metab; 2018 Jul; 13():45-55. PubMed ID: 29789271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
    Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
    PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.
    Aaldijk AS; Verzijl CRC; Jonker JW; Struik D
    Front Endocrinol (Lausanne); 2023; 14():1150222. PubMed ID: 37260446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fundamentals of FGF19 & FGF21 action in vitro and in vivo.
    Adams AC; Coskun T; Rovira AR; Schneider MA; Raches DW; Micanovic R; Bina HA; Dunbar JD; Kharitonenkov A
    PLoS One; 2012; 7(5):e38438. PubMed ID: 22675463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients.
    Gallego-Escuredo JM; Domingo P; Gutiérrez Mdel M; Mateo MG; Cabeza MC; Fontanet A; Vidal F; Domingo JC; Giralt M; Villarroya F
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):527-34. PubMed ID: 23187887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue.
    Adams AC; Yang C; Coskun T; Cheng CC; Gimeno RE; Luo Y; Kharitonenkov A
    Mol Metab; 2012; 2(1):31-7. PubMed ID: 24024127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a crucial amino acid responsible for the loss of specifying FGFR1-KLB affinity of the iodinated FGF21.
    Luo W; Lin XM; Wang TX; Cai JL; Zeng XF; Zhu CR; Li RZ; Wang H; Wu XP
    J Cell Physiol; 2019 Mar; 234(3):2500-2510. PubMed ID: 30317562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia.
    Lan T; Morgan DA; Rahmouni K; Sonoda J; Fu X; Burgess SC; Holland WL; Kliewer SA; Mangelsdorf DJ
    Cell Metab; 2017 Nov; 26(5):709-718.e3. PubMed ID: 28988823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors.
    Wu X; Lemon B; Li X; Gupte J; Weiszmann J; Stevens J; Hawkins N; Shen W; Lindberg R; Chen JL; Tian H; Li Y
    J Biol Chem; 2008 Nov; 283(48):33304-9. PubMed ID: 18829467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural biology of the FGF19 subfamily.
    Beenken A; Mohammadi M
    Adv Exp Med Biol; 2012; 728():1-24. PubMed ID: 22396159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.
    Lee S; Choi J; Mohanty J; Sousa LP; Tome F; Pardon E; Steyaert J; Lemmon MA; Lax I; Schlessinger J
    Nature; 2018 Jan; 553(7689):501-505. PubMed ID: 29342135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.
    Feng S; Dakhova O; Creighton CJ; Ittmann M
    Cancer Res; 2013 Apr; 73(8):2551-62. PubMed ID: 23440425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-specific activities of FGF19 require Klotho beta.
    Lin BC; Wang M; Blackmore C; Desnoyers LR
    J Biol Chem; 2007 Sep; 282(37):27277-27284. PubMed ID: 17627937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform.
    Hultman K; Scarlett JM; Baquero AF; Cornea A; Zhang Y; Salinas CBG; Brown J; Morton GJ; Whalen EJ; Grove KL; Koegler FH; Schwartz MW; Mercer AJ
    J Comp Neurol; 2019 Aug; 527(12):2069-2085. PubMed ID: 30809795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy.
    Itoh N; Ohta H; Konishi M
    Front Endocrinol (Lausanne); 2015; 6():154. PubMed ID: 26483756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
    Henriksson E; Andersen B
    Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in
    Hansen AMK; Vienberg SG; Lykkegaard K; Zhao X; Tingqing G; Han D; Zhang X; Thøgersen H; Sass-Ørum K; Tagmose T; Raun K; Andersen B
    Biochem J; 2018 Sep; 475(18):2985-2996. PubMed ID: 30127091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
    Weng Y; Chabot JR; Bernardo B; Yan Q; Zhu Y; Brenner MB; Vage C; Logan A; Calle R; Talukdar S
    PLoS One; 2015; 10(3):e0119104. PubMed ID: 25790234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.